Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street PDR S&P Retail ETF (XRT) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
State Street PDR S&P Retail ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs State Street PDR S&P Retail ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.11 (market cap $29.60B), while State Street PDR S&P Retail ETF trades at $88.84. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYXRT
Market Cap
$29.60B
Sector
HealthBroad Market / Factor
52-Week High
$491.22$92.35
52-Week Low
$205.48$77.28
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

State Street PDR S&P Retail ETF

XRT trades at $88.81, down 1.96% today, with a bullish technical signal from moving averages and key indicators like ADX suggesting a strong trend. The ETF's valuation metrics are not available in the provided data, but recent news highlights retail sector focus amid mixed economic signals. A dividend of $0.19 is scheduled for June 2026, adding income potential.

The outlook for XRT is cautiously optimistic, driven by positive retail sales trends and potential Fed easing, but risks include consumer sentiment pressures and inflation. Analyst sentiment is mixed, with some downgrades citing macro headwinds, making it essential to monitor economic indicators for sustained growth.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About State Street PDR S&P Retail ETF

XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.

Read more on XRT